BioMarin Pharmaceuticals
BMRN
587 hedge funds and large institutions have $10.1B invested in BioMarin Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 247 increasing their positions, 184 reducing their positions, and 81 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 247 | Existing positions reduced: 184
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
11% more call options, than puts
Call options by funds: $81.1M | Put options by funds: $73M
7% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 81
0% less funds holding
Funds holding: 588 → 587 (-1)
1.61% less ownership
Funds ownership: 97.8% → 96.19% (-1.6%)
10% less capital inflows, than outflows
Capital inflows: $1.58B | Capital outflows: $1.76B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$156M |
| 2 |
Millennium Management
New York
|
+$127M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$87.7M |
| 4 |
Morgan Stanley
New York
|
+$81.6M |
| 5 |
Renaissance Technologies
New York
|
+$53.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$516M |
| 2 |
Elliott Investment Management
West Palm Beach,
Florida
|
-$247M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$121M |
| 4 |
Primecap Management
Pasadena,
California
|
-$118M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$110M |
BMRN Hedge Fund Activity: Q2 2025 in Review
587 of the 7,633 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2025, worth a combined $10.1B — down 22% from $13B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new BMRN positions and 81 closed out — a net gain of 6 holders — while 247 added to existing stakes and 184 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $156M. The largest seller was Capital Research Global Investors, cutting an estimated $516M.
- 587 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2025, down from 588 in Q1 2025.
- Funds reported $10.1B of BioMarin Pharmaceuticals stock for Q2 2025, down 22% quarter-over-quarter.
- 87 funds opened new BioMarin Pharmaceuticals positions in Q2 2025 and 81 closed out, a net change of +6 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2025 was AQR Capital Management, an estimated $156M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2025 was Capital Research Global Investors, an estimated $516M sold.
Based on aggregated 13F filings for Q2 2025.